Benign prostatic hyperplasia: A new metabolic disease of the aging male and its correlation with sexual dysfunctions

International Journal of Endocrinology

Volumn 2014, Issue , 2014, Pages

  Corona, Giovanni ^a   Vignozzi, Linda ^b   Rastrelli, Giulia ^b   Lotti, Francesco ^b   Cipriani, Sarah ^b   Maggi, Mario ^b  

^a BELLARIA HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; STEROID 5ALPHA REDUCTASE INHIBITOR; TADALAFIL; TAMSULOSIN; TESTOSTERONE; VARDENAFIL;

AGING; ALCOHOL CONSUMPTION; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; EATING HABIT; EXERCISE; GLUCOSE INTOLERANCE; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPOGONADISM; INFLAMMATION; LIFESTYLE MODIFICATION; LOWER URINARY TRACT SYMPTOM; MALE SEXUAL DYSFUNCTION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; PROSTATECTOMY; REVIEW; RISK FACTOR; SMOKING; TESTOSTERONE BLOOD LEVEL; WEIGHT REDUCTION;

EID: 84897750169     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2014/329456     Document Type: Review

References (138)

1. Salvioli S., Monti D., Lanzarini C., Conte M., Pirazzini C., Bacalini M. G., Garagnani P., Giuliani C., Fontanesi F., Ostan R., Bucci L., Sevini F., Yani S. L., Barbieri A., Lomartire L., Borelli V., Vianello D., Bellavista E., Martucci M., Cevenini E., Pini E., Scurti M., Biondi F., Santoro A., Capri M., Franceschi C., Immune system, cell senescence, aging and longevity-inflamm-aging reappraised. Current Pharmaceutical Design 2013 19 9 1675 1679
2. Corona G., Rastrelli G., Morelli A., Vignozzi L., Mannucci E., Maggi M., Hypogonadism and metabolic syndrome. Journal of Endocrinological Investigation 2011 34 7 557 567 2-s2.0-80054089894 10.3275/7806
3. Corona G., Rastrelli G., Maggi M., Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes. Best Practice & Research Clinical Endocrinology & Metabolism 2013 27 7 557 579
4. Gacci M., Vignozzi L., Sebastianelli A., Salvi M., Giannessi C., de Nunzio C., Tubaro A., Corona G., Rastrelli G., Santi R., Serni G., Nesi S., Carini M., Maggi M., Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer and Prostatic Diseases 2013 16 1 101 106
5. Hayward S. W., Cunha G. R., The prostate: development and physiology. Radiologic Clinics of North America 2000 38 1 1 14 2-s2.0-0033955151 (Pubitemid 30059002)
6. Cunha G. R., Ricke W. A., A historical perspective on the role of stroma in the pathogenesis of benign prostatic hyperplasia. Differentiation 2011 82 4-5 168 172 2-s2.0-80052961767 10.1016/j.diff.2011.04.002
7. Shannon J. M., Cunha G. R., Characterization of androgen binding and deoxyribonucleic acid synthesis in prostate-like structures induced in the urothelium of testicular feminized (Tfm/Y) mice. Biology of Reproduction 1984 31 1 175 183 2-s2.0-0021206851 (Pubitemid 14026866)
8. Cunha G. R., Chung L. W. K., Stromal-epithelial interactions. I. Induction of prostatic phenotype in urothelium of testicular feminized (Tfm/y) mice. Journal of Steroid Biochemistry 1981 14 12 1317 1324 2-s2.0-0019799945 10.1016/0022-4731(81)90338-1 (Pubitemid 12136929)
9. Haughney P. C., Hayward S. W., Dahiya R., Cunha G. R., Species-specific detection of growth factor gene expression in developing murine prostatic tissue. Biology of Reproduction 1998 59 1 93 99 2-s2.0-0031799065 10.1095/biolreprod59.1.93 (Pubitemid 28304358)
10. Lee S. O., Tian J., Huang C. K., Ma Z., Lai K. P., Hsiao H., Jiang M., Yeh S., Chang C., Suppressor role of androgen receptor in proliferation of prostate basal epithelial and progenitor cells. Journal of Endocrinology 2012 213 2 173 182
11. Corona G., Baldi E., Maggi M., Androgen regulation of prostate cancer: where are we now? Journal of Endocrinological Investigation 2011 34 3 232 243 2-s2.0-79957902488 10.3275/7501
12. Berry S. J., Coffey D. S., Walsh P. C., Ewing L. L., The development of human benign prostatic hyperplasia with age. The Journal of Urology 1984 132 3 474 479 2-s2.0-0021149603 (Pubitemid 14026148)
13. Walsh P. C., Wilson J. D., The induction of prostatic hypertrophy in the dog with androstanediol. Journal of Clinical Investigation 1976 57 4 1093 1097 2-s2.0-0011187358
14. Abrams P., LUTS, BPH, BPE, BPO: a plea for the logical use of correct terms. Reviewsin Urology 1999 1 2 65
15. Liu C.-C., Huang S.-P., Li W.-M., Wang C.-J., Chou Y.-H., Li C.-C., Huang C.-H., Wu W.-J., Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men. Urology 2007 70 4 677 680 2-s2.0-35648954048 10.1016/j.urology.2007.05.025 (Pubitemid 350030220)
16. Martin S., Lange K., Haren M. T., Taylor A. W., Witter G., Risk factors for progression and improvement of lower urinary tract symptoms (LUTS) in a prospective cohort of men. The Journal of Urology 2013 191 1 130 137 10.1016/j.juro.2013.06.018
17. Wu F. C. W., Tajar A., Pye S. R., Silman A. J., Finn J. D., O'Neill T. W., Bartfai G., Casanueva F., Forti G., Giwercman A., Huhtaniemi I. T., Kula K., Punab M., Boonen S., Vanderschueren D., Petrone L., Cilotti A., Borghs H., Slowikowska-Hilczer J., Walczak-Jedrzejowska R., Wu F., Silman A., O'Neill T., Finn J., Steer P., Lee D., Pye S., Ocampo M., Lage M., Bartfai G., Földesi I., Fejes I., Korrovitz P., Jiang M., Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European male aging study. Journal of Clinical Endocrinology and Metabolism 2008 93 7 2737 2745 2-s2.0-47549107694 10.1210/jc.2007-1972 (Pubitemid 352008544)
18. Tenover J. S., Effects of testosterone supplementation in the aging male. Journal of Clinical Endocrinology and Metabolism 1992 75 4 1092 1098 2-s2.0-0026742650 10.1210/jc.75.4.1092
19. Holmäng S., Mårin P., Lindstedt G., Hedelin H., Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate 1993 23 2 99 106 2-s2.0-0027425903 (Pubitemid 23289891)
20. Shigehara K., Sugimoto K., Konaka H., Iijima M., Fukushima M., Maeda Y., Mizokami A., Koh E., Origasa H., Iwamoto T., Namiki M., Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male 2011 14 1 53 58 2-s2.0-79751520081 10.3109/13685538.2010.518178
21. Haider A., Gooren L. J., Padungtod P., Saad F., Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. Andrologia 2009 41 1 7 13 2-s2.0-58449124744 10.1111/j.1439-0272.2008.00880.x
22. Kalinchenko S., Vishnevskiy E. L., Koval A. N., Mskhalaya G. J., Saad F., Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study. Aging Male 2008 11 2 57 61 2-s2.0-45849143339 10.1080/13685530801953994 (Pubitemid 351878773)
23. Pearl J. A., Berhanu D., François N., Masson P., Zargaroff S., Cashy J., McVary K. T., Testosterone supplementation does not worsen lower urinary tract symptoms. The Journal of Urology 2013 190 5 1828 1833
24. Ko Y. H., Moon du G., Moon K. H., Testosterone replacement alone for testosterone deficiency syndrome improves moderate lower urinary tract symptoms: one year follow-up. The World Journal of Men's Health 2013 31 1 47 52
25. Karazindiyanolu S., Çayan S., The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. Aging Male 2008 11 3 146 149 2-s2.0-52949086447 10.1080/13685530802290438
26. Comeglio P., Morelli A., Cellai I., Vignozzi L., Sarchielli E., Filippi S., Maneschi E., Corcetto F., Corno C., Gacci M., Vannelli G. B., Maggi M., Opposite effects of tamoxifen on metabolic syndrome induced bladder and prostate alterations: a role for GPR30/GPER? Prostate 2014 74 1 10 28 10.1002/pros.22723
27. Nicholson T. M., Ricke W. A., Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 2011 82 4-5 184 199 2-s2.0-80052967110 10.1016/j.diff.2011.04.006
28. Chavalmane A. K., Comeglio P., Morelli A., Filippi S., Fibbi B., Vignozzi L., Sarchielli E., Marchetta M., Failli P., Sandner P., Saad F., Gacci M., Vannelli G. B., Maggi M., Sex steroid receptors in male human bladder: expression and biological function. Journal of Sexual Medicine 2010 7 8 2698 2713 2-s2.0-77955250255 10.1111/j.1743-6109.2010.01811.x
29. Marmorston J., Lombardo L. J. Jr., Myers S. M., Gierson H., Stern E., Hopkins C. E., Urinary excretion of estrone, estradiol and estriol by patients with prostatic cancer and benign prostate hypertrophy. The Journal of Urology 1965 93 2 287 295 2-s2.0-12144269342
30. Partin A. W., Oesterling J. E., Epstein J. I., Horton R., Walsh P. C., Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. The Journal of Urology 1991 145 2 405 409 2-s2.0-0026089071
31. Meikle A. W., Stephenson R. A., McWhorter W. P., Skolnick M. H., Middleton R. G., Effects of age, sex steroids, and family relationships on volumes of prostate zones in men with and without prostate cancer. Prostate 1995 26 5 253 259 2-s2.0-0029065626 10.1002/pros.2990260505
32. Hammarsten J., Damber J.-E., Karlsson M., Knutson T., Ljunggren Ö., Ohlsson C., Peeker R., Smith U., Mellström D., Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer and Prostatic Diseases 2009 12 2 160 165 2-s2.0-67349202437 10.1038/pcan.2008.50
33. Miwa Y., Kaneda T., Yokoyama O., Association between lower urinary tract symptoms and serum levels of sex hormones in men. Urology 2008 72 3 552 555 2-s2.0-50249116103 10.1016/j.urology.2008.04.023
34. St. Sauver J. L., Jacobson D. J., McGree M. E., Girman C. J., Klee G. G., Lieber M. M., Jacobsen S. J., Associations between longitudinal changes in serum estrogen, testosterone, and bioavailable testosterone and changes in benign urologic outcomes. American Journal of Epidemiology 2011 173 7 787 796 2-s2.0-79953906189 10.1093/aje/kwq438
35. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., Van Kerrebroeck P., Victor A., Wein A., The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003 61 1 37 49 2-s2.0-0037253578 10.1016/S0090-4295(02)02243-4 (Pubitemid 36151708)
36. de Nunzio C., Aronson W., Freedland S. J., Giovannucci E., Parsons J. K., The correlation between metabolic syndrome and prostatic diseases. European Urology 2012 61 3 560 570 2-s2.0-84856381421 10.1016/j.eururo.2011.11.013
37. Bourke J. B., Griffin J. P., Diabetes mellitus in patients with benign prostatic hyperplasia. British Medical Journal 1968 4 629 492 493 2-s2.0-0014427801
38. Hammarsten J., Högstedt B., Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. European Urology 2001 39 2 151 158 2-s2.0-0035108041 10.1159/000052430 (Pubitemid 32171181)
39. Michel M. C., Mehlburger L., Schumacher H., Bressel H.-U., Goepel M., Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. The Journal of Urology 2000 163 6 1725 1729 2-s2.0-0034080050 (Pubitemid 30366722)
40. Joseph M. A., Harlow S. D., Wei J. T., Sarma A. V., Dunn R. L., Taylor J. M. G., James S. A., Cooney K. A., Doerr K. M., Montie J. E., Schottenfeld D., Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. American Journal of Epidemiology 2003 157 10 906 914 2-s2.0-0037541574 10.1093/aje/kwg051 (Pubitemid 36555050)
41. Seim A., Hoyo C., Østbye T., Vatten L., The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT Study. British Journal of Urology International 2005 96 1 88 92 2-s2.0-21744441211 10.1111/j.1464-410X.2005.05573.x (Pubitemid 40942875)
42. Nandeesha H., Koner B. C., Dorairajan L. N., Sen S. K., Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clinica Chimica Acta 2006 370 1-2 89 93 2-s2.0-33746044904 10.1016/j.cca.2006.01.019 (Pubitemid 44080171)
43. Lotti F., Corona G., Vignozzi L., Rossi M., Maseroli E., Cipriani S., Gacci M., Forti G., Maggi M., Metabolic syndrome and prostate abnormalities in male subjects of infertile couples. Asian Journal of Andrology 2014
44. Vikram A., Jena G., Ramarao P., Insulin-resistance and benign prostatic hyperplasia: the connection. European Journal of Pharmacology 2010 641 2-3 75 81 2-s2.0-77954085409 10.1016/j.ejphar.2010.05.042
45. Kim J. C., Lee J.-Y., Kim J. H., Lee S.-H., Oh C. Y., Lee S. W., Yoo S. J., Chung B. H., Effects of obesity on lower urinary tract symptoms in Korean BPH patients. Asian Journal of Andrology 2009 11 6 663 668 2-s2.0-71049165916 10.1038/aja.2009.62
46. Parsons J. K., Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Current Bladder Dysfunction Reports 2010 5 4 212 218 2-s2.0-77956261394 10.1007/s11884-010-0067-2
47. Kim J. M., Song P. H., Kim H. T., Moon K. H., Effect of obesity on prostate-specific antigen, prostate volume, and international prostate symptom score in patients with benign prostatic hyperplasia. Korean Journal of Urology 2011 52 6 401 405 2-s2.0-79959834793 10.4111/kju.2011.52.6.401
48. Bourke J. B., Griffin J. P., Hypertension, diabetes mellitus, and blood groups in benign prostatic hypertrophy. British Journal of Urology 1966 38 1 18 23 2-s2.0-0013875130
49. Dahle S. E., Chokkalingam A. P., Gao Y.-T., Deng J., Stanczyk F. Z., Hsing A. W., Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. The Journal of Urology 2002 168 2 599 604 2-s2.0-0036074655 (Pubitemid 34793304)
50. Glynn R. J., Campion E. W., Bouchard G. R., Silbert J. E., The development of benign prostatic hyperplasia among volunteers in the normative aging study. American Journal of Epidemiology 1985 121 1 78 90 2-s2.0-0021918346 (Pubitemid 15150691)
51. Sidney S., Quesenberry C. P. Jr., Sadler M. C., Guess H. A., Lydick E. G., Cattolica E. V., Incidence of surgically treated benign prostatic hypertrophy and of prostate cancer among blacks and whites in a prepaid health care plan. American Journal of Epidemiology 1991 134 8 825 829 2-s2.0-0025718971
52. Wang S., Mao Q., Lin Y., Wu J., Wang X., Zheng X., Xie L., Body mass index and risk of BPH: a meta-analysis. Prostate Cancer and Prostatic Diseases 2012 15 3 265 272 2-s2.0-83655172436 10.1038/pcan.2011.65
53. Lotti F., Corona G., Colpi G. M., Filimberti E., Degli Innocenti S., Mancini M., Baldi E., Noci I., Forti G., Adorini L., Maggi M., Elevated body mass index correlates with higher seminal plasma interleukin 8 levels and ultrasonographic abnormalities of the prostate in men attending an andrology clinic for infertility. Journal of Endocrinological Investigation 2011 34 10 336 342 2-s2.0-83455208806
54. Freeman M. R., Solomon K. R., Cholesterol and prostate cancer. Journal of Cellular Biochemistry 2004 91 1 54 69 2-s2.0-2342614947 10.1002/jcb.10724
55. Swyer G., Cholesterol content of normal and enlarged prostates. Cancer Research 1942 2 372 375
56. Nandeesha H., Koner B. C., Dorairajan L. N., Sen S. K., Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clinica Chimica Acta 2006 370 1-2 89 93 2-s2.0-33746044904 10.1016/j.cca.2006.01.019 (Pubitemid 44080171)
57. Gupta A., Gupta S., Pavuk M., Roehrborn C. G., Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology 2006 68 6 1198 1205 2-s2.0-33845308799 10.1016/j.urology.2006.09.034 (Pubitemid 44880381)
58. Lekili M., Müezzinolu T., Uyanik B. S., Büyüksu C., Serum lipid levels in benign prostatic hyperplasia. World Journal of Urology 2006 24 2 210 213 2-s2.0-33744900124 10.1007/s00345-006-0062-6 (Pubitemid 43842553)
59. Zucchetto A., Tavani A., Dal Maso L., Gallus S., Negri E., Talamini R., Franceschi S., Montella M., La Vecchia C., History of weight and obesity through life and risk of benign prostatic hyperplasia. International Journal of Obesity 2005 29 7 798 803 2-s2.0-21244473633 10.1038/sj.ijo.0802979 (Pubitemid 40897017)
60. Parsons J. K., Bergstrom J., Barrett-Connor E., Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. British Journal of Urology International 2008 101 3 313 318 2-s2.0-37849030164 10.1111/j.1464-410X.2007.07332.x
61. Bourke J. B., Griffin J. P., Hypertension, diabetes mellitus, and blood groups in benign prostatic hypertrophy. British Journal of Urology 1966 38 1 18 23 2-s2.0-0013875130
62. Gann P. H., Hennekens C. H., Longcope C., Verhoek-Oftedahl W., Grodstein F., Stampfer M. J., A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate 1995 26 1 40 49 2-s2.0-0028861415 10.1002/pros.2990260109
63. Seim A., Hoyo C., Østbye T., Vatten L., The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT Study. British Journal of Urology International 2005 96 1 88 92 2-s2.0-21744441211 10.1111/j.1464-410X.2005.05573.x (Pubitemid 40942875)
64. Rohrmann S., Smit E., Giovannucci E., Platz E. A., Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). International Journal of Obesity 2005 29 3 310 316 2-s2.0-14744286456 10.1038/sj.ijo.0802881 (Pubitemid 40333230)
65. Joseph M. A., Harlow S. D., Wei J. T., Sarma A. V., Dunn R. L., Taylor J. M. G., James S. A., Cooney K. A., Doerr K. M., Montie J. E., Schottenfeld D., Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. American Journal of Epidemiology 2003 157 10 906 914 2-s2.0-0037541574 10.1093/aje/kwg051 (Pubitemid 36555050)
66. Hammarsten J., Högstedt B., Holthuis N., Mellström D., Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer and Prostatic Diseases 1998 1 3 157 162 2-s2.0-0001154983 (Pubitemid 128545860)
67. Ozden C., Ozdal O. L., Urgancioglu G., Koyuncu H., Gokkaya S., Memis A., The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. European Urology 2007 51 1 199 206 2-s2.0-33751414540 10.1016/j.eururo.2006.05.040 (Pubitemid 44821513)
68. Park H. K., Lee H. W., Lee K. S., Byun S.-S., Jeong S. J., Hong S. K., Lee S. E., Park J. H., Lee S. B., Kim K. W., Relationship between lower urinary tract symptoms and metabolic syndrome in a community-based elderly population. Urology 2008 72 3 556 560 2-s2.0-50249119570 10.1016/j.urology.2008.03.043
69. Yim S. J., Cho Y. S., Joo K. J., Relationship between metabolic syndrome and prostate volume in korean men under 50 years of age. Korean Journal of Urology 2011 52 6 390 395 2-s2.0-79959820777 10.4111/kju.2011.52.6.390
70. Jeong J. H., Kim E. T., Kim D. K., Association of metabolic syndrome and benign prostate enlargement in young Korean males. Korean Journal of Urology 2011 52 11 757 762 2-s2.0-84255162153 10.4111/kju.2011.52.11.757
71. Byun H. K., Sung Y. H., Kim W., Jung J. H., Song J. M., Chung H. C., Relationships between prostate-specific antigen, prostate volume, and components of metabolic syndrome in healthy Korean men. Korean Journal of Urology 2011 53 11 774 778
72. Yang T. K., Hsieh J. T., Chen S. C., Chang H. C., Yang H. J., Huang K. H., Metabolic syndrome associated with reduced lower urinary tract symptoms in middle-aged men receiving health checkup. Urology 2012 80 5 1093 1097
73. Park Y. W., Kim S. B., Kwon H., Kang H. C., Cho K., Lee K. I., Kim Y. J., Lee J. H., The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome. Urology 2013 82 3 674 679
74. Corona G., Mannucci E., Petrone L., Schulman C., Balercia G., Fisher A. D., Chiarini V., Forti G., Maggi M., A comparison of NCEP-ATPIII and IDF metabolic syndrome definitions with relation to metabolic syndrome-associated sexual dysfunction. Journal of Sexual Medicine 2007 4 3 789 796 2-s2.0-34249036769 10.1111/j.1743-6109.2007.00498.x (Pubitemid 46779316)
75. Corona G., Rastrelli G., Vignozzi L., Mannucci E., Maggi M., Testosterone, cardiovascular disease and the metabolic syndrome. Best Practice and Research 2011 25 2 337 353 2-s2.0-79952541665 10.1016/j.beem.2010.07.002
76. Kupelian V., McVary K. T., Hall S. A., Link C. L., Aiyer L. P., Mollon P., Tamimi N., Rosen R. C., McKinlay J. B., Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. The Journal of Urology 2013 189 1 S107 S114 2-s2.0-67649770208 10.1016/j.juro.2009.04.025
77. Lotti F., Corona G., Maseroli E., Rossi M., Silverii A., Degl'innocenti S., Rastrelli G., Forti G., Maggi M., Clinical implications of measuring prolactin levels in males of infertile couples. Andrology 2013 1 5 764 771
78. Litwin M. S., McNaughton-Collins M., Fowler F. J. Jr., Nickel J. C., Calhoun E. A., Pontari M. A., Alexander R. B., Farrar J. T., O'Leary M. P., Alexander R. B., Landis J. R., Litwin M. S., Nickel J. C., O'Leary M. P., Pontari M. A., Schaeffer A. J., Barry M. J., Bennett C. L., Bushman W., Calhoun E. A., Ceri H., Cifelli D., Duncan J., Farrar J. T., Feldman H. I., Fowler F. J. Jr., Hunter D., Jarvi K., Kusek J., McNaughton-Collins M., Nadler R. B., Nyberg L. M., Ponniah S., Propert K. J., Ruggieri M. R., Shoskes D. A., The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. The Journal of Urology 1999 162 2 369 375 2-s2.0-0032855823 10.1016/S0022-5347(05)68562-X (Pubitemid 29434343)
79. Roehrborn C. G., Nuckolls J. G., Wei J. T., Steers W., The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics. British Journal of Urology International 2007 100 4 813 819 2-s2.0-34548396884 10.1111/j.1464-410X.2007.07061.x (Pubitemid 47360180)
80. Nickel J. C., Roehrborn C. G., O'Leary M. P., Bostwick D. G., Somerville M. C., Rittmaster R. S., The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. European Urology 2008 54 6 1379 1384 2-s2.0-55749103206 10.1016/j.eururo.2007.11.026
81. di Silverio F., Gentile V., de Matteis A., Mariotti G., Giuseppe V., Luigi P. A., Sciarra A., Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. European Urology 2003 43 2 164 175 2-s2.0-0037326098 10.1016/S0302-2838(02)00548-1 (Pubitemid 36221971)
82. Schenk J. M., Kristal A. R., Neuhouser M. L., Tangen C. M., White E., Lin D. W., Kratz M., Thompson I. M., Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. American Journal of Epidemiology 2010 171 5 571 582 2-s2.0-77249147858 10.1093/aje/kwp406
83. Vignozzi L., Rastrelli G., Corona G., Gacci M., Forti G., Maggi M., Benign prostatic hyperplasia: a new metabolic disease? Journal of Endocrinological Investigation 2014
84. Adorini L., Penna G., Fibbi B., Maggi M., Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia: annals of the New York Academy of Sciences. Annals of the New York Academy of Sciences 2010 1193 146 152 2-s2.0-77951249848 10.1111/j.1749-6632. 2009.05299.x
85. Penna G., Fibbi B., Amuchastegui S., Cossetti C., Aquilano F., Laverny G., Gacci M., Crescioli C., Maggi M., Adorini L., Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. Journal of Immunology 2009 182 7 4056 4064 2-s2.0-64249163290 10.4049/jimmunol.0801875
86. Vignozzi L., Cellai I., Serni R., Morelli A., Sarchielli E., Comeglio P., Filippi S., Maneschi E., Gacci M., Carini M., Piccinni M.-P., Saad F., Adorini L., Vannelli G. B., Maggi M., Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. Journal of Endocrinology 2012 214 1 31 43 2-s2.0-83455211370 10.1530/JOE-11-0289
87. Vignozzi L., Gacci M., Cellai I., Santi R., Corona G., Morelli A., Rastrelli G., Comeglio P., Sebastanelli A., Maneschi E., Nesi G., de Nunzio C., Tubaro A., Mannucci E., Carini M., Maggi M., Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate 2013 73 8 789 800
88. Vignozzi L., Gacci M., Cellai I., Morelli A., Maneschi E., Comeglio P., Santi R., Filippi S., Sebastianelli A., Nesi G., Serni S., Carini M., Maggi M., PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate 2013 73 13 1391 1402
89. Penna G., Mondaini N., Amuchastegui S., Degli Innocenti S., Carini M., Giubilei G., Fibbi B., Colli E., Maggi M., Adorini L., Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. European Urology 2007 51 2 524 533 2-s2.0-33845570300 10.1016/j.eururo.2006.07.016 (Pubitemid 44937795)
90. Penna G., Fibbi B., Amuchastegui S., Corsiero E., Laverny G., Silvestrini E., Chavalmane A., Morelli A., Sarchielli E., Vannelli G. B., Gacci M., Colli E., Maggi M., Adorini L., The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kB pathways. Prostate 2009 69 5 480 493 2-s2.0-61949322951 10.1002/pros.20896
91. Fibbi B., Penna G., Morelli A., Adorini L., Maggi M., Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. International Journal of Andrology 2010 33 3 475 488 2-s2.0-77951918078 10.1111/j.1365-2605. 2009.00972.x
92. Lotti F., Maggi M., Interleukin 8 and the male genital tract. Journal of Reproductive Immunology 2013 100 1 54 65 10.1016/j.jri.2013.02.004
93. Morelli A., Comeglio P., Filippi S., Sarchielli E., Cellai I., Vignozzi L., Yehiely-Cohen R., Maneschi E., Gacci M., Carini M., Adorini L., Vannelli G. B., Maggi M., Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome. The Journal of Steroid Biochemistry and Molecular Biology 2012 132 1-2 80 92
94. Filippi S., Vignozzi L., Morelli A., Chavalmane A. K., Sarchielli E., Fibbi B., Saad F., Sandner P., Ruggiano P., Vannelli G. B., Mannucci E., Maggi M., Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. Journal of Sexual Medicine 2009 6 12 3274 3288 2-s2.0-77950805904 10.1111/j.1743-6109.2009.01467.x
95. Vignozzi L., Morelli A., Filippi S., Comeglio P., Chavalmane A. K., Marchetta M., Toce M., Yehiely-Cohen R., Vannelli G. B., Adorini L., Maggi M., Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. Journal of Sexual Medicine 2011 8 1 57 77 2-s2.0-78650769613 10.1111/j.1743-6109.2010.02073.x
96. Vignozzi L., Morelli A., Sarchielli E., Comeglio P., Filippi S., Cellai I., Maneschi E., Serni S., Gacci M., Carini M., Piccinni M.-P., Saad F., Adorini L., Vannelli G. B., Maggi M., Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. Journal of Endocrinology 2012 212 1 71 84 2-s2.0-83455211370 10.1530/JOE-11-0289
97. Morelli A., Comeglio P., Filippi S., Sarchielli E., Vignozzi L., Maneschi E., Cellai I., Gacci M., Lenzi A., Vannelli G. B., Maggi M., Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit. Prostate 2013 73 4 428 441
98. Oelke M., Bachmann A., Descazeaud A., Emberton M., Gravas S., Michel M. C., Ndow J., Nordling J., de la Rosette J. J., EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. European Urology 2013 64 1 118 140
99. Mondul A. M., Giovannucci E., Platz E. A., A prospective study of obesity and incidence and progression of lower urinary tract symptoms. The Journal of Urology 2013 05477 05479 10.1016/j.juro.2013.08.110
100. Corona G., Rastrelli G., Monami M., Saad F., Luconi M., Lucchese M., Facchiano E., Sforza A., Forti G., Mannucci E., Maggi M., Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. European Journal of Endocrinology 2013 168 6 829 843
101. Hamer M., Chida Y., Intake of fruit, vegetables, and antioxidants and risk of type 2 diabetes: systematic review and meta-analysis. Journal of Hypertension 2007 25 12 2361 2369 2-s2.0-35848947950 10.1097/HJH. 0b013e3282efc214 (Pubitemid 350060373)
102. Dauchet L., Amouyel P., Hercberg S., Dallongeville J., Fruit and vegetable consumption and risk of coronary heart disease: a meta-analysis of cohort studies. Journal of Nutrition 2006 136 10 2588 2593 2-s2.0-33749499884 (Pubitemid 44521618)
103. He F. J., Nowson C. A., MacGregor G. A., Fruit and vegetable consumption and stroke: meta-analysis of cohort studies. The Lancet 2006 367 9507 320 326 2-s2.0-31444443311 10.1016/S0140-6736(06)68069-0 (Pubitemid 43151465)
104. Suzuki S., Platz E. A., Kawachi I., Willett W. C., Giovannucci E., Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. American Journal of Clinical Nutrition 2002 75 4 689 697 2-s2.0-0036193840 (Pubitemid 34250682)
105. Kristal A. R., Arnold K. B., Schenk J. M., Neuhouser M. L., Goodman P., Penson D. F., Thompson I. M., Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. American Journal of Epidemiology 2008 167 8 925 934 2-s2.0-41649119115 10.1093/aje/kwm389 (Pubitemid 351521732)
106. Rohrmann S., Giovannucci E., Willett W. C., Platz E. A., Fruit and vegetable consumption, intake of micronutrients, and benign prostatic hyperplasia in US men. American Journal of Clinical Nutrition 2007 85 2 523 529 2-s2.0-33846867017 (Pubitemid 46220958)
107. Liang T., Liao S., Inhibition of steroid 5 α -reductase by specific aliphatic unsaturated fatty acids. Biochemical Journal 1992 285 2 557 562 2-s2.0-0026721962
108. Block G., Dietrich M., Norkus E. P., Morrow J. D., Hudes M., Caan B., Packer L., Factors associated with oxidative stress in human populations. American Journal of Epidemiology 2002 156 3 274 285 2-s2.0-0036682194 10.1093/aje/kwf029 (Pubitemid 34810481)
109. Tewari R., Rajender S., Natu S. M., Dalela D., Goel A., Goel M. M., Tandon P., Diet, obesity, and prostate health: are we missing the link? Journal of Andrology 2012 33 5 763 776
110. Platz E. A., Kawachi I., Rimm E. B., Colditz G. A., Stampfer M. J., Willett W. C., Giovannucci E., Physical activity and benign prostatic hyperplasia. Archives of Internal Medicine 1998 158 21 2349 2356 2-s2.0-0032561696 (Pubitemid 28536488)
111. Parsons J. K., Kashefi C., Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. European Urology 2008 53 6 1228 1235 2-s2.0-42749095533 10.1016/j.eururo.2008.02.019
112. Gacci M., Corona G., Salvi M., Vignozzi L., McVary K. T., Kaplan S. A., Roehrborn C. G., Serni S., Mirone V., Carini M., Maggi M., A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α -blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. European Urology 2012 61 5 994 1003 2-s2.0-84859422428 10.1016/j.eururo.2012.02.033
113. McVary K. T., Monnig W., Camps J. L. Jr., Young J. M., Tseng L.-J., van den Ende G., Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. The Journal of Urology 2007 177 3 1071 1077 2-s2.0-33846810223 10.1016/j.juro.2006.10.055 (Pubitemid 46216352)
114. McVary K. T., Roehrborn C. G., Kaminetsky J. C., Auerbach S. M., Wachs B., Young J. M., Esler A., Sides G. D., Denes B. S., Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. The Journal of Urology 2007 177 4 1401 1407 2-s2.0-33947266450 10.1016/j.juro.2006.11.037 (Pubitemid 46435965)
115. Stief C. G., Porst H., Neuser D., Beneke M., Ulbrich E., A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology 2008 53 6 1236 1244 2-s2.0-42749084255 10.1016/j.eururo.2008.01.075
116. Roehrborn C. G., McVary K. T., Elion-Mboussa A., Viktrup L., Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. The Journal of Urology 2008 180 4 1228 1234 2-s2.0-50949119951 10.1016/j.juro.2008.06.079
117. Porst H., McVary K. T., Montorsi F., Sutherland P., Elion-Mboussa A., Wolka A. M., Viktrup L., Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. European Urology 2009 56 4 727 736. Corrigendum. European Urology. Vol. 59, no. 6, pp. 2082, 2011 2-s2.0-79955637753 10.1016/j.eururo.2011.03.001
118. Tamimi N. A. M., Mincik I., Haughie S., Lamb J., Crossland A., Ellis P., A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. British Journal of Urology International 2010 106 5 674 680 2-s2.0-77955896740 10.1111/j.1464-410X.2010.09204.x
119. Porst H., Kim E. D., Casabé A. R., Mirone V., Secrest R. J., Xu L., Sundin D. P., Viktrup L., Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. European Urology 2011 60 5 1105 1113 2-s2.0-80053308004 10.1016/j.eururo.2011.08.005
120. Egerdie R. B., Auerbach S., Roehrborn C. G., Costa P., Garza M. S., Esler A. L., Wong D. G., Secrest R. J., Tadalafil 2.5 or 5mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. Journal of Sexual Medicine 2012 9 1 271 281 2-s2.0-84855385961 10.1111/j.1743-6109.2011.02504.x
121. Oelke M., Giuliano F., Mirone V., Xu L., Cox D., Viktrup L., Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. European Urology 2012 61 5 917 925 2-s2.0-84859427322 10.1016/j.eururo.2012.01.013
122. Brock G., Broderick G., Roehrborn C. G., Xu L., Wong D., Viktrup L., Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction. British Journal of Urology International 2013 112 7 990 997
123. Dmochowski R., Roehrborn C., Klise S., Xu L., Kaminetsky J., Kraus S., Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-Week clinical trial. The Journal of Urology 2010 183 3 1092 1097 2-s2.0-75849123577 10.1016/j.juro.2009.11.014
124. Yokoyama O., Yoshida M., Kim S. C., Wang C. J., Imaoka T., Morisaki Y., Viktrup L., Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men. International Journal of Urology 2013 20 2 193 201
125. Giuliano F., Ückert S., Maggi M., Birder L., Kissel J., Viktrup L., The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. European Urology 2013 63 3 506 516
126. Gacci M., Eardley I., Giuliano F., Hatzichristou D., Kaplan S. A., Maggi M., McVary K. T., Mirone V., Porst H., Roehrborn C. G., Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. European Urology 2011 60 4 809 825 2-s2.0-80052269812 10.1016/j.eururo.2011.06.037
127. Andersson K.-E., de Groat W. C., McVary K. T., Lue T. F., Maggi M., Roehrborn C. G., Wyndaele J. J., Melby T., Viktrup L., Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourology and Urodynamics 2011 30 3 292 301 2-s2.0-79952749220 10.1002/nau.20999
128. Fibbi B., Morelli A., Vignozzi L., Filippi S., Chavalmane A., De Vita G., Marini M., Gacci M., Vannelli G. B., Sandner P., Maggi M., Characterization of phosphodiesterase Type 5 expression and functional activity in the human male lower urinary tract. Journal of Sexual Medicine 2010 7 1 59 69 2-s2.0-74049146047 10.1111/j.1743-6109.2009.01511.x
129. Morelli A., Sarchielli E., Comeglio P., Filippi S., Mancina R., Gacci M., Vignozzi L., Carini M., Vannelli G. B., Maggi M., Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. Journal of Sexual Medicine 2011 8 10 2746 2760 2-s2.0-80053566810 10.1111/j.1743-6109.2011.02416.x
130. Morelli A., Filippi S., Sandner P., Fibbi B., Chavalmane A. K., Silvestrini E., Sarchielli E., Vignozzi L., Gacci M., Carini M., Vannelli G. B., Maggi M., Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. Journal of Sexual Medicine 2009 6 6 1594 1608 2-s2.0-66749140292 10.1111/j.1743-6109.2009.01249.x
131. Filippi S., Morelli A., Sandner P., Fibbi B., Mancina R., Marini M., Gacci M., Vignozzi L., Vannelli G. B., Carini M., Forti G., Maggi M., Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007 148 3 1019 1029 2-s2.0-33847049918 10.1210/en.2006-1079
132. Vignozzi L., Filippi S., Comeglio P., Cellai I., Morelli A., Maneschi E., Sarchielli E., Gacci M., Carini M., Vannelli G. B., Maggi M., Tadalafil effect on metabolic syndrome-associated bladder alterations: an experimental study in a rabbit model. Journal of Sexual Medicine 2013 73 4 428 441 10.1002/pros.22584
133. Morelli A., Filippi S., Comeglio P., Sarchielli E., Chavalmane A. K., Vignozzi L., Fibbi B., Silvestrini E., Sandner P., Gacci M., Carini M., Vannelli G. B., Maggi M., Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats. Journal of Sexual Medicine 2010 7 1 107 120 2-s2.0-74049117944 10.1111/j.1743-6109.2009.01558.x
134. Behr-Roussel D., Oger S., Caisey S., Sandner P., Bernabé J., Alexandre L., Giuliano F., Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats. European Urology 2011 59 2 272 277 2-s2.0-78650702653 10.1016/j.eururo.2010.10.037
135. Gacci M., Vittori G., Tosi N., Siena G., Rossetti M. A., Lapini A., Vignozzi L., Serni S., Maggi M., Carini M., A randomized, placebo-controlled study to assess safety and efficacy of Vardenafil 10mg and Tamsulosin 0.4mg vs. Tamsulosin 0.4mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Journal of Sexual Medicine 2012 9 6 1624 1633 2-s2.0-84859742715 10.1111/j.1743-6109.2012.02718.x
136. Kinsella K., Gist Y.,. Older Workers, Retirement, and Pensions. A Comparative International Chartbook. Washington, DC: U.S. Census Bureau and U.S. National Institute on Aging, and U.S. Census Bureau. International Data Base, 1995, http://www.census.gov/ipc/www/idbnew.html
137. Parsons J. K., Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. The Journal of Urology 2007 178 2 395 401 2-s2.0-34447102992 10.1016/j.juro.2007.03.103 (Pubitemid 47030484)
138. Morelli A., Sarchielli E., Comeglio P., Filippi S., Vignozzi L., Marini M., Rastrelli G., Maneschi E., Cellai I., Persani L., Adorini L., Vannelli G. B., Maggi M., Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits. Molecular and Cellular Endocrinology 2013 382 1 107 119